Clofibrate Side Effects
Not all side effects for clofibrate may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to clofibrate: oral capsule liquid filled
In addition to its needed effects, some unwanted effects may be caused by clofibrate. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking clofibrate:Rare
- Chest pain
- irregular heartbeat
- shortness of breath
- stomach pain (severe) with nausea and vomiting
If any of the following side effects occur while taking clofibrate, check with your doctor or nurse as soon as possible:Rare
- Blood in urine
- cough or hoarseness
- decrease in urination
- fever or chills
- lower back or side pain
- painful or difficult urination
- swelling of feet or lower legs
Some of the side effects that can occur with clofibrate may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Decreased sexual ability
- increased appetite or weight gain (slight)
- muscle aches or cramps
- sores in mouth and on lips
- stomach pain, gas, or heartburn
- unusual tiredness or weakness
For Healthcare Professionals
Applies to clofibrate: oral capsule
In general, the most common adverse effects due to clofibrate therapy are gastrointestinal in nature (especially nausea) and may subside over time or with a decreased dosage.
Cholelithiasis and cholecystitis (sometimes requiring surgery or resulting in pancreatitis) occur more frequently in patients receiving clofibrate than in patients receiving placebo.
Gastrointestinal reactions may include nausea, vomiting, diarrhea, gastritis, weight loss or gain, and gallstones (during prolonged therapy).
Patients diagnosed with rhabdomyolysis are usually asymptomatic clinically several days after discontinuing clofibrate, but the muscle enzymes may remain elevated for a more prolonged period. Severe renal disease may increase the risk of myopathies, perhaps because of accumulation of the active metabolite clofibric acid.
Musculoskeletal effects (myopathy) typically occur as a "flu-like" syndrome (myalgia, cramps, muscle weakness, and arthralgia). Rhabdomyolysis with an accompanying increase in creatinine kinase and creatinine phosphokinase (CPK) has been reported in patients with renal disease.
Electrolyte disturbances like hyperkalemia have been reported in patients with renal insufficiency who receive clofibrate.
Central nervous system depressant effects may include fatigue, weakness, drowsiness, and/or dizziness. Headache has also been reported.
Hematologic adverse effects may include leukopenia, anemia, eosinophilia, agranulocytosis, and potentiation of anticoagulant effects. Because of these effects, some clinicians recommend periodic monitoring of blood counts.
Cardiovascular complications may include various arrhythmias and altered angina pectoris. Swelling and phlebitis have occurred at xanthomata sites.
Renal dysfunction (including dysuria, hematuria, proteinuria, and decreased urine output) has been reported. Acute renal failure and interstitial nephritis have also been reported.
Decreased libido (primarily in men) and impotence have been reported.
Hepatic disorders may include elevated liver enzymes and/or hepatomegaly. (Liver biopsy, when performed in this setting, is usually normal.) Clofibrate should be used cautiously for patients with a history of jaundice or liver disease.
Dermatologic reactions which occur in about 2% of patients may include urticaria, rash, dry skin, and alopecia. Erythema multiforme, toxic epidermal necrolysis, and Stevens-Johnson syndrome have occurred rarely.
One case of a hypersensitivity reaction occurring as eosinophilic pneumonia has been reported.
Fever, which occurred on rechallenge with clofibrate, has been reported in one case.
Oncologic effects of tumor growth in rodents have been associated with many lipid-lowering drugs. Clofibrate has been associated with liver, pancreatic and testicular tumors in rats. Long-term clinical trials are needed to define the risk of cancer in humans.
More about clofibrate
- Other brands: Atromid-S
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.